Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Gains from Sales and Divestitures: 2010-2024

Historic Gains from Sales and Divestitures for Lineage Cell Therapeutics (LCTX) over the last 14 years, with Dec 2024 value amounting to $67,000.

  • Lineage Cell Therapeutics' Gains from Sales and Divestitures changed negligibly% to $67,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $67,000, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $67,000 for FY2024, which is 16.25% down from last year.
  • As of FY2024, Lineage Cell Therapeutics' Gains from Sales and Divestitures stood at $67,000, which was down 16.25% from $80,000 recorded in FY2023.
  • Lineage Cell Therapeutics' Gains from Sales and Divestitures' 5-year high stood at $80,000 during FY2023, with a 5-year trough of $31,000 in FY2022.
  • Moreover, its 3-year median value for Gains from Sales and Divestitures was $67,000 (2024), whereas its average is $59,333.
  • In the last 5 years, Lineage Cell Therapeutics' Gains from Sales and Divestitures spiked by 30,443.93% in 2020 and then slumped by 50.00% in 2022.
  • Over the past 5 years, Lineage Cell Therapeutics' Gains from Sales and Divestitures (Yearly) stood at $73,000 in 2020, then fell by 15.07% to $62,000 in 2021, then crashed by 50.00% to $31,000 in 2022, then soared by 158.06% to $80,000 in 2023, then fell by 16.25% to $67,000 in 2024.